---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-016709"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:50:35.274222+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics reports Q4/FY24 net loss $169M; cash $879.5M; zelenectide pevedotin shows 65% ORR in mUC

## Summary
- Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.
- Net loss $169.0M ($2.90 per share) for FY2024 vs $180.7M ($5.08 per share) in FY2023.
- Phase 1 Duravelo-1: 65% ORR (13/20) for zelenectide pevedotin + pembrolizumab in first-line mUC; no Grade 4/5 TRAEs of interest.
- FDA Fast Track granted for zelenectide pevedotin in NECTIN4-amplified TNBC and NSCLC; new Phase 1/2 trials planned in 2025.
- R&D expenses $173.0M in FY2024, up from $156.5M in FY2023, driven by zelenectide pevedotin development.

## SEC filing metadata
- accession: 0001104659-25-016709
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465925016709/0001104659-25-016709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465925016709/tm257327d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-016709
- JSON: https://secwatch.observer/filing/0001104659-25-016709.json
- Plain text: https://secwatch.observer/filing/0001104659-25-016709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.